The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy

The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy

ABSTRACTThe clinical development of 4–1BB agonists for cancer immunotherapy has raised substantial interest during the past decade. The first generation of 4–1BB agonistic antibodies entering the clinic, urelumab (BMS-663513) and utomilumab (PF-05082566), failed due to (liver) toxicity or lack of ef...

Full description

Bibliographic Details
Main Authors: Christina Claus, Claudia Ferrara-Koller, Christian Klein
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:mAbs
Subjects:
CD137
4-1BB
TNFRSF9
cancer immunotherapy
costimulatory agonist
4-1BB agonists
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2023.2167189

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2023.2167189

Similar Items